KR20210111779A - C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도 - Google Patents

C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도 Download PDF

Info

Publication number
KR20210111779A
KR20210111779A KR1020217022048A KR20217022048A KR20210111779A KR 20210111779 A KR20210111779 A KR 20210111779A KR 1020217022048 A KR1020217022048 A KR 1020217022048A KR 20217022048 A KR20217022048 A KR 20217022048A KR 20210111779 A KR20210111779 A KR 20210111779A
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
group
halogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217022048A
Other languages
English (en)
Korean (ko)
Inventor
돈 장
지롱 펭
마이클 니콜라스 그레코
마이클 존 코스탄조
마이클 앨런 그린
Original Assignee
베타 파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베타 파마, 인크. filed Critical 베타 파마, 인크.
Publication of KR20210111779A publication Critical patent/KR20210111779A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5004—Acyclic saturated phosphines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217022048A 2018-12-14 2019-12-14 C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도 Withdrawn KR20210111779A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779960P 2018-12-14 2018-12-14
US62/779,960 2018-12-14
PCT/US2019/066414 WO2020124060A1 (en) 2018-12-14 2019-12-14 Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
KR20210111779A true KR20210111779A (ko) 2021-09-13

Family

ID=71077551

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217022048A Withdrawn KR20210111779A (ko) 2018-12-14 2019-12-14 C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도

Country Status (15)

Country Link
US (1) US12258365B2 (https=)
EP (1) EP3893872B1 (https=)
JP (1) JP2022513215A (https=)
KR (1) KR20210111779A (https=)
CN (1) CN113412112B (https=)
AU (1) AU2019395282A1 (https=)
BR (1) BR112021011547A2 (https=)
CA (1) CA3122575A1 (https=)
EA (1) EA202191541A1 (https=)
IL (1) IL283589A (https=)
MX (1) MX2021006982A (https=)
SG (1) SG11202105872RA (https=)
TW (1) TW202039500A (https=)
WO (1) WO2020124060A1 (https=)
ZA (1) ZA202104000B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969955B (zh) * 2023-09-25 2023-12-19 中国药科大学 一种[1,2,4]三唑[4,3-b]哒嗪类化合物及其制法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA030141B1 (ru) 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
ES2598530T3 (es) 2010-07-14 2017-01-27 Betta Pharmaceuticals Co., Ltd. Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
ES2877799T3 (es) * 2015-12-31 2021-11-17 Shanghai Pharmaceuticals Holding Co Ltd Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones

Also Published As

Publication number Publication date
CN113412112A (zh) 2021-09-17
EP3893872B1 (en) 2024-07-17
CN113412112B (zh) 2024-06-11
EA202191541A1 (ru) 2022-01-21
TW202039500A (zh) 2020-11-01
WO2020124060A1 (en) 2020-06-18
SG11202105872RA (en) 2021-07-29
EP3893872A4 (en) 2022-08-10
EP3893872A1 (en) 2021-10-20
US12258365B2 (en) 2025-03-25
MX2021006982A (es) 2021-09-10
AU2019395282A1 (en) 2021-07-08
ZA202104000B (en) 2022-08-31
BR112021011547A2 (pt) 2021-08-31
CA3122575A1 (en) 2020-06-18
US20220064194A1 (en) 2022-03-03
IL283589A (en) 2021-07-29
JP2022513215A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
CN112300194B (zh) 一类稠环吡啶酮类化合物、制备方法和用途
CN111094289B (zh) 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
EA036932B1 (ru) Производные аммония, способ их получения и фармацевтические композиции, содержащие их
CN114072404B (zh) Ret选择性抑制剂及其制备方法和用途
CN108698996A (zh) 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物
CN115340559A (zh) Shp2磷酸酶杂环类抑制剂的制备及其应用
AU2020404978A1 (en) CD206 modulators their use and methods for preparation
CN110950867A (zh) 一种fgfr4激酶抑制剂及其制备方法和用途
EP4378943A1 (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
CN112209925A (zh) Ret选择性抑制剂及其制备方法和用途
KR20210111779A (ko) C-met 억제제로서 유기 인-치환 화합물 및 이의 치료학적 용도
TWI894448B (zh) Ctla-4小分子降解劑及其應用
CN113166109A (zh) 氨基吡啶类化合物及其制备方法和用途
CN111825694A (zh) 稠环化合物、其制备方法及用途
CN115340561A (zh) Shp2磷酸酶稠环类抑制剂的制备及其应用
CN114728980A (zh) 吡唑类化合物
CN114195800A (zh) Usp7抑制剂
WO2025102600A1 (zh) 一种新型杂环化合物
CN115960109A (zh) 稠环类shp2磷酸酶抑制剂的制备及其应用
CN104024261B (zh) 咪唑并哒嗪化合物
HK40045058B (en) Triazolo-pyrimidine compounds and uses thereof
HK40027808B (en) Triazolo-pyrimidine compounds and uses thereof
CN104024261A (zh) 咪唑并哒嗪化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203